12 March 2024
12 March 2024
The placebo-controlled ADVANCE-2 trial enrolled 454 adult subjects with negative schizophrenia symptoms.
Top-line results from the trial are expected to be released next month.
Saranas presented the data as part of a late-breaking session at the Cardiovascular Research Technologies (CRT) 2024 conference in Washington, DC.
A Phase Ib trial of TU2218 in combination with Keytruda is underway in the US for treating advanced solid tumours.
Allergy Therapeutics reports that no new safety signals were identified in the first part of the trial involving healthy volunteers.
Affluent’s artificial urinary sphincter Artus device is being evaluated as a treatment for urinary incontinence.
The study is evaluating the efficacy of ABTL0812 plus chemotherapy regimen FOLFIRINOX in metastatic pancreatic cancer patients.
Sanofi presented the data as part of a late-breaking session at the American Academy of Dermatology (AAD) 2024 conference in San Diego, US.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
